The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.
Haloperidol quickly quiets severe behavior in autistic kids yet leaves learning untouched, so pair it with parent training from day one.
01Research in Context
What this study did
Doctors gave 0.25–4 mg of haloperidol each day to autistic kids . After four weeks they checked two things: how loud or harmful the kids acted, and how fast the kids learned a simple color game.
The study was a double-blind RCT. Half the kids got real pills, half got sugar pills. No one knew who had which until the end.
What they found
Haloperidol cut tantrums, pacing, and hitting by a lot. The change showed up fast, within the first week.
But the drug did nothing for learning. Kids on haloperidol scored the same on the color game as kids on placebo.
How this fits with other research
Breider et al. (2024) now offers a safer way. Their parent-training program also lowered noncompliance and irritability, and the gains lasted six months. No pills needed.
Farmer et al. (2012) went one step further. They kept the antipsychotic and added parent training on top. Behavior problems dropped even more, showing the drug can be a bridge while you teach skills.
Parsons et al. (2013) looked at 24 later drug trials. They warn that most autism meds, including haloperidol, still lack long-term safety data. Use the smallest dose for the shortest time, and always pair it with behavior plans.
Why it matters
You now know haloperidol can calm a crisis but will not teach the child anything. Start behavior skills training right away so the child gains replacement behaviors while the drug keeps him safe. Plan to fade the medicine once the family has the teaching tools in place.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Open the parent-training manual tonight and schedule the first caregiver coaching session while the prescribing doc monitors dose.
02At a glance
03Original abstract
This double-blind and placebo-controlled clinical trial in autistic children had three objectives: (a) to replicate earlier findings that haloperidol administration is associated with a significant reduction of behavioral symptoms; (b) to further assess its safety when given on a short-term basis; and (c) to assess whether it has an effect on discrimination learning. Forty-five children, 2.02 to 7.58 years old (M = 4.49), completed this crossover design, with random assignment to treatment sequences. Haloperidol was shown to be a powerful therapeutic agent when administered for 4 weeks and free of side effects; at doses ranging from 0.25 to 4.0 mg/day (M = 0.844), there was a clinically and statistically significant reduction of a variety of symptoms. Under the given conditions, the children failed to learn on either haloperidol or placebo.
Journal of autism and developmental disorders, 1989 · doi:10.1007/BF02211843